CG Oncology (NASDAQ:CGON) is now covered by analysts at Wedbush. They set an "outperform" rating and a $70.00 price target on the stock.
How Positive Cretostimogene Trial Updates And Leadership Moves At CG Oncology (CGON) Have Changed Its Investment Story [Yahoo! Finance]
CG Oncology, Inc. (CGON) is a Buy on Cancer Treatment Development: Truist Securities [Yahoo! Finance]
New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer
CG Oncology Announces New Board Member and Board Transition [Yahoo! Finance]